KLK3 and cancer: Patients with a PSA level higher than 20 ng/mL had an 11% (TR, 0.89; 95% CI, 0.88-0.91) reduction in median survival time for nonprostate cancer–specific mortality, and those with a Gleason score of 8 or higher had a 13% (TR, 0.87; 95% CI, 0.85-0.88) reduction in median survival time for nonprostate cancer–specific mortality (eFigure 1 in Supplement 1).